Thislist of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming theirpharmaceutical drug candidates. Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematicchemical names , and for which the effort to generate nonproprietary names may not be warranted, see article ondrug nomenclature . Instead, these compounds are usually given a number for internal reference at the company. To distinguish the numbered compounds from different companies (or academic laboratories), each compound number is prefixed with a letter code indicating the company that developed the compound, that claimsintellectual property on that compound etc. The letter code is conceived by companies themselves who should be interested in creating a unique code. Three main methods are found for prefixing the numeric identifier – with a space (gap),[ 1] [ 2] [ 3] [ 4]
For example, ABT-199 is a compound developed atAbbott Laboratories , and this name has been used in early publications of research results. Later the compound was assigned theInternational Nonproprietary Name (INN)venetoclax . Similarly, other compounds may be given aUSAN orBAN for example. Finally, the compound may be given atrade name for example for marketing purposes.
A long list of code designations with correspondingtrade names can be found in Appendix IV of the USP Dictionary, see article ondrug nomenclature .
Note that this convention of composing compound identifiers from a company identifier followed by a number is not always followed. For example, the letter code may reflect a therapeutic/disease area or an internal project name. A randomly picked example is SC for spinal cord injury.[ 5]
ARQ –ArQule ARRYArray BioPharma ASP –Astellas Pharma [ 9] AT –Arecor Therapeutics [ 10] ATB –Antibe Therapeutics ATL –Antisense Therapeutics Limited, Australia AVXS –AveXis , in May 2018 acquired by Novartis AY –Ayerst , later Wyeth-Ayerst, ultimately acquired by Pfizer AZD –AstraZeneca BAN –BioArctic Neuroscience AB, Sweden BAY –Bayer AG BB –Bluebird Bio BCX –Laboratoires Biocodex BI –Boehringer Ingelheim BIIB –Biogen BMS –Bristol-Myers Squibb BMY – Bristol-Myers Co., merging in 1989 into Bristol-Myers Squibb BRL – Beecham Research Labs, merged with SmithKline into SmithKline Beecham which merged into GlaxoSmithKline BTC –The Boots Company plc C –Laboratoires Cassenne CAM –Cambridge Antibody Technology , acquired by AstraZeneca CAS –Cassella Farbwerke Mainkur Aktiengesellschaft , later Hoechst, later Sanofi CAT –Cannasat Therapeutics Inc., renamed 2010Cynapsus Therapeutics CAT –Cambridge Antibody Technology , acquired byAstraZeneca CC –Celgene CE –Pfizer CGS –Ciba Geigy CP – Pfizer. CP refers toC. P. Pharmaceuticals , a subsidiary of Pfizer[ 11] CSL –CSL Limited , an Australian biopharmaceutical company CVX –CovX , acquired byPfizer in 2008 CYT –Cytopia of Australia, acquired byYM Biosciences , subsequently byGilead Sciences [ 12] D –Draco division ofAstra AB , nowAstraZeneca DMP – DuPont Merck Pharmaceuticals, a joint venture betweenDuPont andMerck ; becameDuPont Pharmaceuticals in 1998 DPC –DuPont Pharmaceuticals , acquired byBristol-Myers Squibb in 2001 DS –Daiichi Sankyo DX –Dyax EAG –Eagle Pharmacy , a United States pharmaceutical compounding company[ 13] EIDD –Emory Institute for Drug Development EMD –Merck KGaA (E. Merck), Darmstadt, Germany (refers to laboratory founder Emanuel Merck inDarmstadt ) ETC –Esperion Therapeutics , acquired by Pfizer in 2003, independent again since 2008 F –Forest Labs , acquired byActavis FCE –Farmitalia-Carlo Erba , laterPharmacia AB, later Pharmacia & Upjohn, acquired byPfizer FF –Fujifilm FG –FibroGen FK –Fermentek FPI –Fusion Pharmaceuticals FS –F-star G – J. R. Geigy AG, ultimately merged intoNovartis G –Genta Inc. GDC –Genentech Likely Genentech Development Candidate[ 14] [ 15] GEH –GE Healthcare GNE –Genentech internal reference number, company pipeline uses GDC- prefixes[ 14] [ 16] GP – Geigy, merged with CIBA in 1971 to becomeCiba-Geigy , nowNovartis GR –GlaxoSmithKline GS –Gilead Sciences GS –Gesynta Pharma [ 17] GSK –GlaxoSmithKline H – Hässle division ofAstra AB , nowAstraZeneca HCV –ViroPharma HOE –Hoechst AG ICI –Imperial Chemical Industries , acquired byAkzoNobel and merged intoZeneca Group by the merger of the pharmaceutical operations. Now part ofAstraZeneca IDN –Idun Pharmaceuticals , acquired byPfizer ILY –Ilypsa , acquired byAmgen in 2007 INNO –CytRx ION –Ionis IPI –Infinity Pharmaceuticals , Inc ISIS –Isis Pharmaceuticals (renamed Ionis Pharmaceuticals in 2015) JNJ –Johnson & Johnson KOS –Kosan Biosciences KPT –Karyopharm Therapeutics KU –KuDOS Pharmaceuticals KW –Kyowa Hakko L –Labaz Group , acquired byElf Aquitaine in 1973 to formSanofi LU –Lundbeck LY –Eli Lilly MBX –MBX Biosciences [ 18] MCN –McNeil Laboratories , now part of Johnson & Johnson MDCO –The Medicines Company MDL –Merrell Dow Pharmaceuticals MEDI –MedImmune , acquired byAstraZeneca [ 19] MEM –Memory Pharmaceuticals MM –MindMed MRT –Monte Rosa Therapeutics [ 20] MGX –Victory Pharma MK –Merck & Co. (Merck Sharp & Dohme) MLN –Millennium Pharmaceuticals MT –Micromet , acquired byAmgen in 2012 NBI –Neurocrine Biosciences [ 21] NC –Nycomed NC –Nippon Chemiphar NCX –NicOx NG –Neurogen Corp. NI –Neurimmune NKTR –Nektar Therapeutics NSI –Neuralstem, Inc. NVS –Novartis OCT –Octant Bio OGX –OncoGenex OPC –Otsuka Pharmaceutical Co. OSI –OSI Pharmaceuticals PD –Parke-Davis , nowPfizer PF –Pfizer PHA –Pharmacia , nowPfizer PNU –Pharmacia & Upjohn , nowPfizer PT –Pearl Therapeutics , now part ofAstraZeneca PTI –Proteostasis Therapeutics Inc R –Janssen Pharmaceutica , now part ofJohnson & Johnson (Janssen began as Belgian and Dutch distributor for products ofGedeon Richter Plc. ) RDEA –Ardea Biosciences acquired byAstraZeneca RDX –Ardelyx RXC –Redx Pharma REGN –Regeneron Pharmaceuticals [ 2] RLY –Relypsa RMI –Richardson-Merrell RO –Hoffmann–La Roche RP –ReceptorPharma RPC – Receptos, nowCelgene RTI–Research Triangle Institute (mostly restricted to variousphenyltropanes ) RU –Roussel Uclaf RWJ –R. W. Johnson Pharmaceutical Research Institute , now part of Johnson & Johnson SAGE –Sage Therapeutics SAN –Sandoz Pharmaceuticals , nowNovartis SB –SmithKline Beecham , nowGlaxoSmithKline SC –G.D. Searle , nowPfizer SCH –Schering Corp., laterSchering-Plough SKF –Smith, Kline & French , later merged intoGlaxoSmithKline SLV –Solvay SNS –Sunesis Pharmaceuticals [ 22] SNS –Sensei Biotherapeutics [ 23] SPD –Shire SPI –Spectrum Pharmaceuticals SU –CIBA Pharmaceutical Company (the Summit, NJ site) SU –SUGEN , nowPfizer ^ "ArQule clinical pipeline" . Retrieved2016-09-16 .^a b "Regeneron PCSK9 Antibody REGN727" . Archived fromthe original on 2012-04-16. Retrieved2012-04-17 .^a b "Exelixis HSP90 inhibitor XL888" . Archived fromthe original on 2016-09-18. Retrieved2016-09-16 .^a b "AbbVie pipeline, using ABBV- as prefix" . Retrieved2016-09-16 .^ "SC0806 clinical trial" . Retrieved2018-07-26 .^a b "AbbVie spun out of Abbott" .Chicago Tribune . Retrieved2016-09-15 .^ "ADL5747" . Retrieved2008-03-19 .[dead link ^ "Amgen goes 6-for-6 in Phase III" . 17 March 2014. Retrieved2014-11-25 .^ "Overview of R&D Pipeline" (PDF) . Retrieved2018-12-30 .^ "Our Portfolio" .Arecor Therapeutics . Retrieved12 June 2023 .^ Drawbaugh, Tom Bergin (16 November 2015)."How Pfizer has shifted U.S. profits overseas for years" .Reuters . Retrieved2019-11-06 . ^ "Edison outlook report on YM Biosciences" (PDF) . Retrieved2016-09-19 .^ "Eagle Pharmacy – Pharmaceutical Compounding" . Retrieved2016-04-26 .^a b "Genentech Pipeline" . Retrieved2016-09-29 .^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GDC-0152".Journal of Medicinal Chemistry .59 (23):10549– 10563.doi :10.1021/acs.jmedchem.6b01022 .PMID 27682507 . ^ Crawford, Terry D.; Romero, F. Anthony; Lai, Kwong Wah; Tsui, Vickie; Taylor, Alexander M.; De Leon Boenig, Gladys; Noland, Cameron L.; Murray, Jeremy; Ly, Justin; Choo, Edna F.; Hunsaker, Thomas L.; Chan, Emily W.; Merchant, Mark; Kharbanda, Samir; Gascoigne, Karen E.; Kaufman, Susan; Beresini, Maureen H.; Liao, Jiangpeng; Liu, Wenfeng; Chen, Kevin X.; Chen, Zhongguo; Conery, Andrew R.; Côté, Alexandre; Jayaram, Hariharan; Jiang, Ying; Kiefer, James R.; Kleinheinz, Tracy; Li, Yingjie; Maher, Jonathan; et al. (2016). "GNE-272".Journal of Medicinal Chemistry .59 (23):10549– 10563.doi :10.1021/acs.jmedchem.6b01022 .PMID 27682507 . ^ "First patients dosed in phase II study of GS-248 in systemic sclerosis" .Bioworld Science . Clarivate Analytics. Retrieved27 January 2021 .^ "MBX 2109" . Retrieved2024-02-12 .^ "Pipeline – AstraZeneca" . Retrieved2018-12-30 .^ "Monte Rosa MRT-6160" . Retrieved2024-11-25 .^ "Neurocrine Vmat2 inhibitor NBI-98854" . Archived fromthe original on 2015-01-30. Retrieved2016-09-13 .^ "Sunesis BTK inhibitor SNS-062" . Retrieved2016-09-15 .^ "Sensei biotherapeutics anti VISTA" (Press release). October 2021. Retrieved2021-11-29 .^ "Theravance Biopharma Pipeline" .Theravance pipeline background image . Retrieved2024-02-12 .^ "Pipeline" .Terns Pharma pipeline . Retrieved27 January 2021 .^ "TH-302 clinical trial" . Retrieved2013-07-23 .^ "MM&M News" . 2008-12-18. Retrieved2009-02-16 .^ "TransMolecular Product Pipeline" . Archived fromthe original on 2007-07-29. Retrieved2007-11-18 .^ "Pipeline" .Totus Medicines Pipeline . Retrieved25 August 2023 .^ "TOS-358 Clinical Trial" . Retrieved25 August 2023 .^ "Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3Kα with superior anticancer activity" . Retrieved25 August 2023 .^ "Taisho Press Release" . Retrieved2008-01-07 .^ "UCL1684 at pubchem.gov" . Retrieved2018-03-24 .
